Search Within

Carl Ola Landgren

Formats
  1. Meeting Abstract (155)
  2. Journal Article (151)
  3. Review (14)
  4. Research Letter (7)
  5. Book Section (3)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Conference Paper (1)
  9. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (336)
  2. Department of Medicine (336)
  3. Hematologic Malignancies Research (336)
  4. Hematologic Malignancies, Division of (336)
  5. Myeloma (336)
  6. Survivorship Research (132)

More Groups

People
  1. Neha Korde (106)
  2. Sham Mailankody (91)
  3. Alexander Lesokhin (83)
  4. Malin Hultcrantz (81)
  5. Hani Hassoun (77)
  6. Sergio Giralt (73)

More People

Years
  1. 2023 (2)
  2. 2022 (4)
  3. 2021 (21)
  4. 2020 (52)
  5. 2019 (56)
  6. 2018 (51)

More Years

Publications
  1. Blood (102)
  2. Haematologica (25)
  3. Clinical Lymphoma, Myeloma and Leukemia (21)
  4. Leukemia and Lymphoma (16)
  5. Biology of Blood and Marrow Transplantation (13)
  6. Blood Cancer Journal (10)

More Publications

Publishers
  1. American Society of Hematology (109)
  2. Elsevier Inc. (45)
  3. Nature Publishing Group (29)
  4. Ferrata Storti Foundation (25)
  5. Taylor & Francis Group (17)
  6. American Association for Cancer Research (15)

More Publishers

Results (336)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment of high risk (HR) smoldering multiple myeloma (SMM) with carfilzomib, lenalidomide, and dexamethasone (KRd) followed by lenalidomide maintenance (-R): A phase 2 clinical and correlative study
    Meeting Abstract

    Kazandjian, D.; Hill, E.; Morrison, C.; Dew, A.; Korde, N.; Mailankody, S.; Manasanch, E. E.; Kwok, M. L.; Bhutani, M.; Tageja, N.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • The role of (18)F-FDG-PET/CT in characterizing depth of response in high risk smoldering multiple myeloma patients treated with carfilzomib, lenalidomide, and dexamethasone (KRd)
    Meeting Abstract

    Hill, E.; Korde, N.; Morrison, C.; Dew, A.; Carpenter, A.; Epstein, M.; Lu, C.; Choyke, P.; Mena, E.; Lindenberg, L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in relapsed or refractory multiple myeloma: Updated efficacy and safety results of the phase 3 CANDOR study
    Meeting Abstract

    Dimopoulos, M. A.; Quach, H.; Mateos, M. V.; Landgren, O.; Leleu, X.; Siegel, D. S.; Weisel, K.; Gavriatopoulou, M.; Oriol, A.; Rabin, N. K.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Initial whole genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001
    Meeting Abstract

    Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; Iacobuzio-Donahue, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Influence of aging processes on the biology and outcome of multiple myeloma
    Meeting Abstract

    Boyle, E. M.; Williams, L.; Blaney, P.; Ashby, C.; Bauer, M. A.; Walker, B. A.; Choi, J.; Caro, J.; Razzo, B.; Arbini, A. A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A prospective study of circulating chemokines and angiogenesis markers and risk of multiple myeloma and its precursor
    Journal Article

    Hofmann, J. N.; Landgren, O.; Landy, R.; Kemp, T. J.; Santo, L.; McShane, C. M.; Shearer, J. J.; Lan, Q.; Rothman, N.; Pinto, L. A.; more...
    JNCI Cancer Spectrum (2020)

    Fulltext@MSK | Save
  • The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: Is it time for a paradigm shift?
    Review

    Kazandjian, D.; Mo, C. C.; Landgren, O.; Richardson, P. G.
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Peripheral neuropathy and monoclonal gammopathy of undetermined significance: A population-based study including 15,351 cases and 58,619 matched controls
    Correspondence

    Rognvaldsson, S.; Steingrimsson, V.; Turesson, I.; Bjorkholm, M.; Landgren, O.; Kristinsson, S. Y.
    Haematologica (2020)

    Fulltext@MSK | Save
  • Prognostic factors for postrelapse survival after ex vivo CD34(+)-selected (T cell-depleted) allogeneic hematopoietic cell transplantation in multiple myeloma
    Journal Article

    Gomez-Arteaga, A.; Shah, G. L.; Baser, R. E.; Scordo, M.; Ruiz, J. D.; Bryant, A.; Dahi, P. B.; Ghosh, A.; Lahoud, O. B.; Landau, H. J.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save